MC1R is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Diabulimia (a portmanteau of diabetes and bulimia), also known as ED-DMT1 (eating disorder-diabetes mellitus type 1) in the US or T1ED (type 1 eating disorder) in the UK, is an eating disorder in which people with type 1 diabetes deliberately give themselves less insulin than they need or stop taking it altogether for the purpose of weight loss. Diabulimia is not recognized as a formal psychiatric diagnosis in the DSM-5. Because of this, some in the medical or psychiatric communities use the phrases "disturbed eating behavior" or "disordered eating behavior" (DEB in both cases) and disordered eating (DE) are quite common in medical and psychiatric literature addressing patients who have type 1 diabetes and manipulate insulin doses to control weight along with exhibiting bulimic behavior. Diabulimia is caused by a range of factors relating to body image, the regular use of insulin, and emotional well-being. Insulin can cause weight gain, and a person who restricts insulin may lose weight. Insulin restriction can lead to the common symptoms of uncontrolled hyperglycemia, which risks complications and a shorter life expectancy. Treatment involves cognitive behavioral therapy, and other support services offered by a multidisciplinary team who work both in diabetes medicine and on eating disorders. Diabulimia is most common in young people, and most of the severe cases tend to occur in women. Research into effective management strategies is ongoing, with a growing medical consensus on the importance of early intervention with specialist teams.
=== Anterograde neuronal transport === Molecules synthesized in the cell bodies of neurons must be conveyed outward to the distal synapses. This is accomplished via fast anterograde transport. It has been found that APP can mediate interaction between cargo and kinesin and thus facilitate this transport. Specifically, a short peptide 15-amino-acid sequence from the cytoplasmic carboxy-terminus is necessary for interaction with the motor protein. Additionally, it has been shown that the interaction between APP and kinesin is specific to the peptide sequence of APP. In a recent experiment involving transport of peptide-conjugated colored beads, controls were conjugated to a single amino acid, glycine, such that they display the same terminal carboxylic acid group as APP without the intervening 15-amino-acid sequence mentioned above. The control beads were not motile, which demonstrated that the terminal COOH moiety of peptides is not sufficient to mediate transport.
The first large, diverse lineage of short-tailed avialans to evolve were the Enantiornithes, or "opposite birds", so named because the construction of their shoulder bones was in reverse to that of modern birds. Enantiornithes occupied a wide array of ecological niches, from sand-probing shorebirds and fish-eaters to tree-dwelling forms and seed-eaters. While they were the dominant group of avialans during the Cretaceous period, Enantiornithes became extinct along with many other dinosaur groups at the end of the Mesozoic era. Many species of the second major avialan lineage to diversify, the Euornithes (meaning "true birds", because they include the ancestors of modern birds), were semi-aquatic and specialised in eating fish and other small aquatic organisms. Unlike the Enantiornithes, which dominated land-based and arboreal habitats, most early euornithians lacked perching adaptations and likely included shorebird-like species, waders, and swimming and diving species. The latter included the superficially gull-like Ichthyornis and the Hesperornithiformes, which became so well adapted to hunting fish in marine environments that they lost the ability to fly and became primarily aquatic. The early euornithians also saw the development of many traits associated with modern birds, like strongly keeled breastbones, toothless, beaked portions of their jaws (though most non-avian euornithians retained teeth in other parts of the jaws).
=== Genesis === In March 1988, the U.S. government entered into negotiations with Noriega seeking his resignation. Panama was represented at those negotiations by Rómulo Escobar Bethancourt. Negotiations collapsed after several months of lengthy and inconclusive talks; according to Dinges, Noriega had no intentions of ever resigning. On December 15, 1989, the PRD-dominated legislature spoke of "a state of war" between the United States and Panama. It also declared Noriega "chief executive officer" of the government, formalizing a state of affairs that had existed for six years. The U.S. government stated that Noriega's forces were harassing U.S. troops and civilians. Three incidents in particular occurred very near the time of the invasion, and were mentioned by Bush as a reason for the invasion. In a December 16 incident, four U.S. personnel were stopped at a roadblock outside PDF headquarters in the El Chorrillo neighborhood of Panama City. The United States Department of Defense said that the servicemen were traveling unarmed in a private vehicle, and that they attempted to flee the scene only after their vehicle was surrounded by a crowd of civilians and PDF troops. First Lieutenant Robert Paz of the United States Marine Corps was shot and killed in the incident. An American couple who witnessed the incident was also arrested and harassed by the PDF.
Sources: en.wikipedia.org
== Clinical significance == It was hoped that ANGPTL8 or its homolog in humans may provide an effective treatment for type 2 diabetes and perhaps even type I diabetes. Unfortunately, since new data have greatly called into question the ability of ANGPTL8 to increase beta-cell replication, its potential use as a therapy for type 2 diabetes is limited. Inhibition of ANGPTL8 represents a possible therapeutic strategy for hypertriglyceridemia. In a clinical trial, a human ANGPTL3/8 monoclonal antibody reduced the concentration of triglycerides (-70%), and low-density lipoprotein cholesterol (-32%), while increasing HDL- cholesterol (+27%), representing a promising therapy for multiple lipid disorders.
Naturally occurring xenon (54Xe) consists of nine isotopes: seven stable isotopes and two very long-lived radioactive isotopes: double electron capture has been observed in 124Xe (half-life 1.1 ± 0.2stat ± 0.1sys×1022 years), and double beta decay in 136Xe (half-life 2.18 ×1021 years), which are among the longest measured half-lives of all nuclides. The isotopes 126Xe and 134Xe are also predicted to undergo double beta decay, but such decay processes have not been observed. Artificial unstable isotopes have been prepared from 108Xe to 150Xe, the longest-lived of which is 127Xe with a half-life of 36.342 days. All other nuclides have half-lives less than 12 days, most less than one hour. The shortest-lived isotope, 108Xe, has a half-life of 58 μs, and is the heaviest known nuclide with equal numbers of protons and neutrons. Of known isomers, the longest-lived is 131mXe with a half-life of 11.95 days, the second longest of all xenon's nuclides. 129Xe is produced by beta decay of natural or artificial 129I (half-life 16.1 million years); 131mXe, 133Xe, 133mXe, and 135Xe are some of the fission products of both 235U and 239Pu, so are used as indicators of nuclear explosions. The artificial isotope 135Xe is of considerable significance in the operation of nuclear fission reactors. 135Xe has a huge cross section for thermal neutrons, 2.65 million barns, so it acts as a neutron absorber or "poison" that can slow or stop the chain reaction after a period of operation.
Tin (50Sn) is the element with the greatest number of naturally abundant isotopes, 10. Seven, 114-120Sn, are theoretically stable, while the remaining three, 112Sn, 122Sn, and 124Sn, are potentially radioactive to double beta decay, but no decay has been observed. This is generally attributed to the fact that 50 is a "magic number" of protons. In addition, 32 unstable tin isotopes are known, including tin-100 (100Sn) and tin-132 (132Sn), which are both "doubly magic". The longest-lived of these is tin-126 (126Sn), with a half-life about 230,000 years; with all others less than a year and the majority under 20 minutes. The number of known metastable states is very large, including a long series of low-lying states in odd isotopes from 117 on, which gives two nuclides with a longer life than any ground-state radioisotope other than 126: 121mSn, half-life 43.9 years, and 119mSn, half-life 293.1 days.
is large, which results in a larger plastic radius. This implies that the material can plastically deform, and, therefore, is tough. This estimate of the size of the plastic zone beyond the crack tip can then be used to more accurately analyze how a material will behave in the presence of a crack. The same process as described above for a single event loading also applies and to cyclic loading. If a crack is present in a specimen that undergoes cyclic loading, the specimen will plastically deform at the crack tip and delay the crack growth. In the event of an overload or excursion, this model changes slightly to accommodate the sudden increase in stress from that which the material previously experienced. At a sufficiently high load (overload), the crack grows out of the plastic zone that contained it and leaves behind the pocket of the original plastic deformation. Now, assuming that the overload stress is not sufficiently high as to completely fracture the specimen, the crack will undergo further plastic deformation around the new crack tip, enlarging the zone of residual plastic stresses. This process further toughens and prolongs the life of the material because the new plastic zone is larger than what it would be under the usual stress conditions. This allows the material to undergo more cycles of loading. This idea can be illustrated further by the graph of Aluminum with a center crack undergoing overloading events.
Abdel Fattah al-Burhan Abdelrahman al-Burhan (born 11 July 1960) is a Sudanese military officer who has been the leader of Sudan since 2019. Following the Sudanese Revolution in April 2019, he was handed control of the military junta, the Transitional Military Council, a day after it was formed, due to protesters' dissatisfaction with the establishment ties of initial leader Ahmed Awad Ibn Auf. He served as chairman of the TMC until a draft constitutional declaration signed with civilians went into effect on 17 August and a collective head of state Transitional Sovereignty Council was formed on 21 August, also to be initially headed by al-Burhan. The 2020 Juba Agreement allowed al-Burhan to continue to lead the Sovereignty Council for another 20 months, rather than stepping down as planned in February 2021. Al-Burhan seized power in a coup d'état in October 2021, dissolved the Sovereignty Council, and reconstituted it the following month with new membership, keeping himself as chairman. He was formerly the General Inspector of the Sudanese Armed Forces (SAF). He is leading the SAF against the Rapid Support Forces (RSF) in the ongoing Sudanese civil war. Al-Burhan survived an assassination attempt in July 2024.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.